Abstract
Highlights• First economic evaluation of prehabilitation across the whole lung cancer pathway• Cost-effective in early-stage (£3,019/QALY) and late-stage (£6,040/QALY) disease• Remained cost-saving when all survival benefit was removed from the model• Greatest benefit accrued to the most deprived quintile, suggesting reduced inequity• Supports commissioning prehabilitation for all lung cancer patients